Molecular Partners Interim Management Statement Q3 2023: Continued Validation Seen Across the DARPin PortfolioGlobeNewsWire • 10/26/23
Molecular Partners Presents New Data on its Radio DARPin Therapy (RDT) Platform at the EANM 2023 Annual MeetingGlobeNewsWire • 09/13/23
Molecular Partners to Present on its Radio DARPin Therapy (RDT) Platform at SNMMI 2023GlobeNewsWire • 06/27/23
Molecular Partners to Present Positive Data from Ongoing Phase 1 Trial of MP0317 (FAP X CD40) Monotherapy in Patients with Advanced Solid Tumors at the 2023 ASCO Annual MeetingGlobeNewsWire • 05/25/23
Molecular Partners to Participate in RBC Capital 2023 Global Healthcare ConferenceGlobeNewsWire • 05/16/23
Interim Management Statement Q1 2023 of Molecular Partners: Well Capitalized to Pursue Highly Differentiated DARPin Portfolio StrategyGlobeNewsWire • 05/11/23
Molecular Partners to Present Additional Preclinical Data Supporting the Company's Radio DARPin Therapy Platform at AACRGlobeNewsWire • 04/14/23
Molecular Partners Announces Shareholders Approve All Board Proposals at the Annual General MeetingGlobeNewsWire • 04/04/23
Molecular Partners Reports Corporate Highlights From Q4 2022 and Key Financials for Full Year 2022GlobeNewsWire • 03/09/23
Molecular Partners to Hold Conference Call to Discuss Fourth Quarter and Full Year 2022 Results and Present at the 43rd Annual Cowen Health Care ConferenceGlobeNewsWire • 03/02/23
Molecular Partners Presents New Preclinical Data Supporting Its Radio DARPin Therapy PlatformGlobeNewsWire • 02/28/23
Molecular Partners Initiates Clinical Study of Trispecific Candidate MP0533 for the Treatment of Acute Myeloid LeukemiaGlobeNewsWire • 01/16/23
Molecular Partners to Present at 41st Annual JP Morgan Healthcare Conference and Swiss Investor ConferencesGlobeNewsWire • 12/30/22
Molecular Partners Presents New Preclinical Data Supporting its MP0533 DARPin T-Cell Engager for the Treatment of AMLGlobeNewsWire • 12/13/22
Molecular Partners Presents Positive Interim Safety and Mechanistic Data From Ongoing Phase 1 Trial of MP0317 for Treatment of Solid TumorsGlobeNewsWire • 11/10/22
Molecular Partners Announces Acceptance of Oral Presentation at the Annual American Society of Hematology MeetingGlobeNewsWire • 11/03/22
Molecular Partners Announces Upcoming Participation in Investor and Scientific ConferencesGlobeNewsWire • 11/02/22
Interim Management Statement Q3 2022: Continued Progress Across Oncology Programs with First Clinical Data Expected from Phase 1 Trial of MP0317 and Initiation of Phase 1 Trial of MP0533 Anticipated by Year-EndGlobeNewsWire • 10/27/22